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Poster Session II S273therapies. Current therapy includes corticosteroids and immunosup-
pression. Azithromycin has been used to manage BO following lung
transplantation; however it has been reported in fewHSCT patients.
We report our experience in 46 patients receiving azithromycin for
BO.
Methods: IRB approval and patient consent were obtained prior to
review of electronic medical records and theMayo Clinic HSCT da-
tabase. All adult patients who received a HSCT from 1/1/00 to 8/1/
09 and received azithromycin were included. Patients were excluded
if they refused consent for use of medical records for research, re-
ceived azithromycin for prophylaxis or treatment of infection, or
did notmeet criteria for BO according to the 2001 diagnostic criteria
for BO in lung transplantation. BO stage was based on PFTs follow-
ing these criteria. Baseline demographic characteristics and clinical
endpoints were collected including: change in PFTs, therapy re-
ceived, and survival following BO diagnosis.
Results: From 1/1/00 to 8/1/09, 388 patients underwent alloge-
neic HSCT at Mayo Clinic Rochester; 46 received azithromycin
for BO. 342 patients were excluded: consent refused (n5 1), no
azithromycin (n5 306), azithromycin for treatment of infection
(n5 27), azithromycin for prophylaxis of infection (n5 6), BO
stage 0 (n5 2). Primary diagnosis included AML/MDS (n5 21),
ALL (n5 9), MM (n5 5), CLL (n5 4), CML (n5 3), lymphoma
(n5 3), CMML (n5 1). Median age at diagnosis of BO was 48
years (range 19-68). 25/46 (54%) received a MUD allogeneic
HSCT. 17/46 (37%) received reduced intensity conditioning.
24/46 (52%) received. 1200 cGy TBI. Median time from trans-
plant to BO diagnosis was 363 days (range 98-1822 days). Azithro-
mycin dosing regimens ranged from 250 mg thrice weekly to
500 mg daily. 30 patients received systemic corticosteroids, 31 re-
ceived inhaled corticosteroids, 14 received ECP, and 5 receivedTable 1. Pulmonary Function Tests in Patients with Bronchiolitis Obliterans
Pre-transplant At diagnosis of BO 1 month 3 months 6 months 9 months 12 months
FEV1 891/-15 (n5 46) 551/-16 (n5 46) 631/-22 (n5 39) 641/-23 (n5 28) 581/-26 (n5 28) 631/-27 (n5 17) 521/-19 (n5 18)
FEF 25-75 831/-32 (n5 46) 441/-30 (n5 46) 571/-42 (n5 39) 531/-29 (n5 28) 501/-36 (n5 28) 571/-44 (n5 17) 411/-33 (n5 18)
DLCO 801/-16 (n5 41) 561/-12 (n5 39) 601/-15 (n5 31) 621/-15 (n5 21) 601/-15 (n5 16) 611/-16 (n5 12) 601/-15 (n5 16)
BO Stage
0 0 5 2 3 3 0
Potential BO 3 6 5 5 2 1
1 9 5 6 3 4 4
2 16 14 8 5 2 5
3 18 9 7 12 6 8montelukast. PFT changes over time are described in Table 1.
14/46 (30%) have died; with a median follow-up of 1.5 years
(range 0.13-3.97 years) from BO diagnosis, the median survival
from BO diagnosis has not been reached.
Conclusions: Patients receiving azithromycin in addition to stan-
dard therapy for BO maintained stable pulmonary function tests
for the first year following BO diagnosis. The generally favorable
survival following BO warrants further prospective research.310
THE ANCESTRAL HAPLOTYPE A1B8DR3 IS ASSOCIATED WITH IN-
CREASED INCIDENCE OF PULMONARY COMPLICATIONS AFTER ALLOGE-
NEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
Liu, J., Pukiat, S., Hahn, T., McCarthy, Battiwalla M., Jr, P.L. Roswell
Park Cancer Institute, Buffalo, NY
The 3 most common ancestral haplotypes in people of European
descent are A1B8DR3 (5.2%), A2B44DR4 (2.1%) and A3B7DR15
(2.6%). A1B8DR3 is associated with pulmonary autoimmune dis-
eases such as sarcoidosis and Wegener’s granulomatosis. Tumor
necrosis factor alpha (TNF-a) is the cytokine most frequently im-
plicated in the pathobiology of pulmonary complications after
HCT and TNF-a polymorphisms are strongly associated with
the A1B8DR3 haplotype. After observing several cases of pulmo-nary complications in A1B8DR3 patients, we conducted a retro-
spective cohort study to investigate the association of this
haplotype with pulmonary complications after allogeneic HCT.
From 1/1991 to 5/2005, 248 patients received an allogeneic
HCT from a related (N5 183) or unrelated (N5 65) peripheral
blood (n5 35) or marrow (n5 213) donor for myeloid (n5 159)
or lymphoid (n5 89) diseases. The A1B8DR3 haplotype was pres-
ent in 23 (9%), A2B44DR4 in 12 (5%) and A3B7DR15 in 19 (8%)
allogeneic HCT patients, which is higher than reported in normal
donors. Patient and treatment characteristics were: age at HCT 18-
40 years (n5 118, 48%), .40 years (n5 130, 52%); male (n5 155,
63%), European American (n5 234, 94%); KPS 90-100 (n5 159,
64%); VpCyTBI (n5 114), BuTBI (n5 27), BuCy (n5 27), Thio-
TBI (n5 22), CyTBI (n5 18); FluMel (n5 8); ThioCarbo (n5 8),
or Other (n5 24). Pulmonary complications included diffuse alve-
olar hemorrhage (DAH), bronchiolitis obliterans/lung GVHD
(BO/GVHD), viral or fungal pneumonia (VFPn), interstitial pneu-
monitis/ARDS/pleural effusion (IP/ARDS), and any one or more
of these pulmonary complications. There was no association of
A1B8DR3 with DAH or IP/ARDS, however BO/GVHD (17%
vs 4%, p5 0.017) and VFPn (30% vs 0%.p\0.001) were signifi-
cantly more common in patients with A1B8DR3. Any one or
more pulmonary complications was more common, but not signif-
icantly different, in patients with A1B8DR3 (48% vs 32%,
p5 0.16). Conversely, patients with the A2B44DR4 haplotype de-
veloped no pulmonary complications of any kind (0% vs 35%,
p5 0.013). There was no association of A3B7DR15 haplotype
with any pulmonary complications. There was no significant inter-
action for lymphoid/myeloid disease, related/unrelated donor or
male/female recipient between A1B8DR3 and any pulmonary com-
plications. Investigating the relationship between HLA haplotypeand outcome may improve our understanding of the pathogenesis
of pulmonary complications and provide individualized screening
and treatment for this adverse outcome.311
IMPROVED OUTCOME AFTER REDUCED INTENSITY ALLOGENEIC HEMA-
TOPOIETIC STEM CELL TRANSPLANT (RI-HCT) FOR MDS USING TACRO-
LIMUS/SIROLIMUS AS GVHD PROPHYLAXIS
Nakamura, R.1, Palmer, J.2, Chao, J.1, Stiller, T.2, Pullarkat, V.1,
Parker, P.1, Stein, A.1, Snyder, D.1, Cai, J.-L.1, Bhatia, R.1,
Chang, K.3, Wang, S.4, Senitzer, D.1, Forman, S.J.1,
O’Donnell, M.R.1 1 City of Hope National Medical Center, Duarte, CA;
2 City of Hope National Medical Center, Duarte, CA; 3 City of Hope Na-
tional Medical Center, Duarte, CA; 4 City of Hope National Medical Cen-
ter, Duarte, CA
We previously reported an encouraging result with RI-HCT
for MDS (Bone Marrow Transplant 2007) using fludarabine/mel-
phalan (Flu/Mel) conditioning and cyclosporine (CSA)/mycophe-
nolate (MMF) as GVHD prophylaxis. In order to further
improve upon the outcome in the RI-HCT setting, we initiated
a series of clinical trials at City of Hope designed to evaluate the
impact of tacrolimus (FK)/sirolimus (SIR)-based GVHD
S274 Poster Session IIprophylaxis. Here we report the combined, updated results from
a consecutive case-series of 58 patients with MDS who under-
went RI-HCT from 2000 to 2008 and received either CSA/
MMF (n5 29) or FK/SIR (n5 29)-based GVHD prophylaxis.
All patients received Flu 125 mg/m2 and Mel 140 mg/m2 fol-
lowed by allogeneic HCT (PBSC: n5 52, BM: n5 6) from an
HLA-identical sibling (SIB: n5 21) or unrelated donor (MUD:
n5 37). For MUD transplants a short course of methotrexate
was added to CSA/MMF or FK/SIR. The median age was
53.5 years (range: 20-71). Diagnoses at transplant were RA
(n5 21), RARS (n5 1), and RAEB/RAEBT (n5 36). Cytoge-
netic risk was low in 15, intermediate in 20, high in 23 patients.
By IPSS criteria, two had low, 24 had int-1, 20 had int-2, and 12
had high-risk MDS. Fifteen patients had therapy-related MDS
and 13 had a prior autologous HCT. The baseline patient and
transplant characteristics were similar between CSA/MMF and
FK/SIR except for more mismatch transplants in FK/SIR (34%
vs. 10%, p5 0.02). The median follow-up for surviving patients
was 38 months (range: 24-68) for the CSA/MMF group and
16 months (range: 4-39) for the FK/SIR group. All but two pa-
tients engrafted with the median neutrophil recovery at 15 days
(range: 11-39). The 2-year disease-free survival (DFS), relapse,
and non-relapse mortality (NRM) for the entire cohort were
63% (54-70%), 12% (6-24%), and 26% (19-36%), respectively.
By univariate analysis, there was a trend for improved DFS in
FK/SIR (79% at 1 year) compared with CSA/MMF (55%,
p5 0.1). When adjusted for mismatch transplants in multivariate
analysis, the use of FK/SIR was significantly associated with im-
proved DFS (HR5 3.99 [CI: 1.4-11.5], p5 0.01), attributable to
reduced NRM with FK/SIR (HR5 6.14 [CI: 1.5-26.1],
P5 0.01). While we observed no significant difference in grade
II-IV acute GVHD between the two groups, there was a signifi-
cant reduction in grade IV GVHD in FK/SIR (0% versus 26%,
p\0.01). In conclusion, RI-HCT is associated with a promising
long-term result in MDS with improved outcomes using FK/
SIR-based GVHD prophylaxis.312
TOXOPLASMA GONDII INFECTION IN 34 PTS SUBMITTED TO HEMATO-
POIETIC STEM CELL TRANSPLANTATION: ANALYSIS FROM A SINGLE IN-
STITUTION
Vasconcelos, R., Fortier, S.C., Cunha, C.A., Piazzera, F.Z., Morando, J.,
Bitencourt, M.A., Pasquini, R., Zanis Neto, J., Funke, V.,
Bonfim, C.M.S. Federal University of Parana, Curitiba, PR, Brazil
Introduction:Toxoplasmosis is a rare and aggressive infection after
allogeneic HSCT. In Brazil we observe a high incidence of positive
serology before HSCT and therefore many pts are at risk of reacti-
vation.
Objective: Analyze the outcome of 34 pts who developed toxoplas-
mosis infection after SCT in a single institution.
Material and methods: Retrospective analysis of 34 pts submitted
to an allogeneic HSCT who developed toxoplasmosis between 04/
1984 – 11/2007. Age: 1-45ys(M: 20ys). Gender: 17 M/17F. 91%
had a positive serology (IgG) before transplant. Diagnosis: Bone
Marrow failures: 13pts; Malignant diseases: 21pts). Preparatory reg-
imen:BU +CY:18pts;TBI based regimens:9pts; Fludarabine based
regimens:3pts; CY only: 4pts. 25pts (73%) received a HSCT from
related donors while 9pts were transplanted from unrelated ones.
Toxoplasmosis was classified as definitive, probable, possible or iso-
lated infection according to the diagnostic criteria proposed by
EBMTR.In our BMT Unit, PCR tests were performed in blood
and/or cerebrospinal fluid from March 2000 in all suspected cases.
Toxoplasmosis was identified by PCR, biopsies or necropsy. Statis-
tical analysis was performed using SPSS. Overall survival was esti-
mated using the Kaplan-Meier method. Multivariate analysis was
performed by Cox method.
Results: In this group, only 9pts are alive between 1260- 6385 days
after HSCT(M: 3956d) with an OS of 31,8%(5ys). Toxoplasmosis
was diagnosed at a median of 85days after HSCT (range:26- 3035
days).Toxoplasmosis was defined as definitive in 22 pts(12 pts –
necropsy), probable:1pt; possible:6pts and infection:5pts. Site of in-
fection: Disseminated: 2pts; Central Nervous System (CNS):14pts;lung 8pts; liver: 1pt; ocular: 2pts; skin: 1pt and heart:1pt. Toxoplas-
mosis infection(only):5pts. Primary graft failure occurred in 5/
34pts and all died (4 deaths were related to toxoplasmosis). Acute
GVHD grade II-IV was observed in 22pts while 11 had Chronic
GVHD(extensive: 9pts). 25pts died between 38-4378days after
SCT (M: 90days) and toxoplasmosis was considered the major
cause of death in 13 pts. Survival was lower in the unrelated group
when compared to the related one even though it did not reach sta-
tistical significance in the univariate analysis (68days  254 days
p5 0.097). All pts with the diagnosis of Bone Marrow failures
died (7 related to toxoplasmosis).
Conclusions: 1) We observed a high mortality rate (52%) in this
group of patients and a high prevalence of CNS infection.313
HORIZONTAL GENE TRANSFER THROUGH APOPTOTIC BODIES CONFERS
A NOVEL MECHANISM OF EPITHELIAL CHIMERISM AFTER ALLOGENEIC
HCT
Waterhouse, M.1, Themeli, M.2, Finke, J.1, Spyridonidis, A.2 1 Freiburg
University Medical Center, Freiburg, Baden Wuettemberg, Germany;
2 Patras University Hospital, Patras, Greece
Animal and human studies have shown that after allogeneic he-
matopoietic cell transplantation (HCT) low percentage of epithe-
lial cells containing donor-derived genome emerge. The
mechanisms underlying this phenomenon are unknown. We inves-
tigated using an in vitro model if horizontal gene transfer could ac-
count as a possible mechanism for epithelial chimerism after
allogeneic HCT. Briefly, keratinocyte HaCaT cells (Y-chromo-
some neg) were cocultivated with non-apoptotic Jurkat cells (Y
chromosome pos) or Jurkat cells in which apoptosis was induced
with Camptothecin. Jurkat cells were labeled with CMFDA or
BrdU in order to track the fate of apoptotic bodies and genomic
material respectively. HaCaT cells co-cultivated with non-apopto-
tic Jurkat cells for 24-72 h did not show any CMFDA, BrdU or
FISH-Y chromosome signal. In contrast, co-cultivation of HaCaT
cells with Jurkat apoptotic bodies resulted in CMFDA signal in
28% of the HaCaT cells, BrdU signal in 18% and Y-chromosome
signal in 3% of the cells. Importantly, BrdU and Y-chromosome
signals were observed in the cytoplasm and within the nucleus of
the HaCaT cells as evaluated by confocal microscopy. Metaphases
from the BrdU+ HaCaT cells confirmed that the BrdU signal was
located within the isolated chromosomes suggesting the creation of
hybrid chromosomes. Incorporation of the transferred genomic
material in the HaCaT host genome was inhibited by cytochalasin
(inhibitor of phagocytosis), increased 3-fold by bafylomicin (inhibi-
tion of lysosomal degradation) and 2-fold when HaCat cells were
repeatedly exposed to Jurkat apoptotic bodies. In order to evaluate
expression of the transferred genomic material, we co-cultivated
HacaT cells with intact or apoptotic GFP-transfected JvM cells.
Cocultivation with non-apoptotic GFP+ cells resulted in no GFP
expression in Hacat cells. In contrast, cocultivation of Hacat cells
with GFP+ apoptotic bodies resulted in a 6-fold increase in the
mean GFP fluorescence in HaCaT cells. Taken together, our in
vitro model suggests horizontal gene transfer through apoptotic
bodies as a possible mechanism explaining epithelial chimerism
after allogeneic HCT.314
CRYPTIC GENOMIC ALTERATIONS IN AML PATIENTS AFTER ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANTATION BY SNP DNA PROFILING
Waterhouse, M., Pfeifer, D., Pantic, M., Alf, Z., Bertz, H., Finke, J.
Freiburg University Medical Center, Freiburg, Baden-Wuettemberg,
Germany
Allogeneic hematopoietic cell transplantation (HCT) is the most
effective curative therapy in many patients with hematologic malig-
nancies such as acute myeloid leukemia (AML). Cytogenetics stud-
ies stratify patients into three groups of prognosis according to the
overall survival. These classifications are not fully predictive of
